Share:
The Company expects to have ibogaine manufactured and in use for research by Q4.
VANCOUVER, BC, March 3, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE:MCUR) (OTCQB:MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in advanced proprietary technology for psychedelic drug discovery, is pleased to announce that it has begun the first stage of manufacturing pharmaceutical grade ibogaine to be used in preclinical and clinical research.
Ibogaine is a naturally occurring psychoactive compound extracted from the root of the
Tabernanthe iboga shrub
, native of the Congo and Gabon.
1 The compound offers therapeutic potential for substance use disorders, and is claimed to be among the most powerful anti-addiction drugs, particularly when used with proper supervision and support. However, natural sources of ibogaine are extremely limited since these plants are at risk of extinction due to the growing global demand and environmental pressures threatening their natural ha
his potential treatment opportunity was confirmed by the company s bioinformatics platform, PsyCollage
VANCOUVER, BC, March 4, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in developing technology to advance psychedelic-related treatments, is pleased to announce that the Company s bioinformatics platform,
PsyCollage, has identified opportunities for ibogaine to support neuroregenerative pathways that the Company believes could be pivotal in treating neuropathic pain and brain trauma.
Ibogaine is a psychoactive substance extracted from the iboga shrub native to West Africa. Contributing to its powerful anti-addiction actions, ibogaine is associated with increases in the levels of brain neurotrophic factors, particularly GDNF and BDNF, which have potent neuroregenerative and neuroprotective properties.
The Company expects to have ibogaine manufactured and in use for research by Q4.
VANCOUVER, BC, March 3, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) a leader in advanced proprietary technology for psychedelic drug discovery, is pleased to announce that it has begun the first stage of manufacturing pharmaceutical grade ibogaine to be used in preclinical and clinical research.
Ibogaine is a naturally occurring psychoactive compound extracted from the root of the
Tabernanthe iboga shrub
, native of the Congo and Gabon.
1 The compound offers therapeutic potential for substance use disorders, and is claimed to be among the most powerful anti-addiction drugs, particularly when used with proper supervision and support. However, natural sources of ibogaine are extremely limited since these plants are at risk of extinction due to the growing global demand and environmental pressures threatening their natural habitat.